Biodel Inc.

Biodel Q3 losses increase

Danbury's Biodel Inc.'s losses climbed 59 percent in its fiscal third quarter as the biopharma booked a noncash loss on stock warrant liability related to its June public offering.

Danbury’s Biodel bares $19.5M stock offering

Danbury drug developer Biodel Inc. plans to raise at least $19.5 million through a stock offering to raise more cash as it continues to refine its formulation for a fast-acting insulin inhalant for diabetics.

Danbury Biodel’s 2Q red ink runs deeper

Danbury biopharma Biodel Inc. plunged deeper into red in the fiscal second quarter, as ongoing development costs for a fast-acting insulin treatment for diabetics continues to chew through its cash horde.

Biodel’s insulin drug moves to next test phase

Danbury's Biodel Inc. says it signed up some 130 diabetics for the next leg of its ongoing study of the efficacy of its ultra-fast-acting synthetic insulin for regulating their blood sugar.

- Advertisement -

Next test phase for Biodel’s insulin formula

Danbury's Biodel Inc. says it signed up some 130 diabetics for the next leg of its ongoing study of the efficacy of its ultra-fast-acting synthetic insulin for regulating their blood sugar.

CT Biodel’s drug milestones mute 1Q loss

Biodel Inc. narrowed its fiscal first-quarter loss while moving the Danbury biopharma a step further in the process toward federal approval for its fast-acting synthetic insulin formulations.

Danbury biopharma Biodel’s 4Q turns red

Danbury biopharma Biodel Inc.'s ongoing development costs for a fast-acting insulin treatment for diabetics pushed it into the red in the fiscal fourth quarter.

Danbury’s Biodel wins lucrative FDA ‘orphan’ tag

In a strong finish to a busy 2012, Danbury biopharma Biodel Inc. says the top U.S. drug regulator has granted "orphan drug" status to its treatment for infants born with a rare condition in which their tiny bodies produce too much insulin.

- Advertisement -

CT’s Biodel wins 2nd grant for diabetes treatment

Danbury bioscience firm Biodel Inc. got a second $582,763 federal grant to fund ongoing development of drug formulations for an artificial pancreas for diabetics.